Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764634 · ClinicalTrials.gov registry record · Phase 2
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
A Phase 2 study, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 440
- Enrollment target
NCT00764634 is a Phase 2 study that has completed, run by DynPort Vaccine Company LLC, A GDIT Company. The registered enrollment target is 440 participants.
The verdict
NCT00764634, a Phase 2 study, has completed, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 440 participants
- Enrollment target
Study Summary
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Interventions
- BIOLOGICAL Placebo (USP sterile saline for injection)
- BIOLOGICAL rBV A/B-40 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00764634
The ClinicalTrials.gov registry entry for NCT00764634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DynPort Vaccine Company LLC, A GDIT Company, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (USP sterile saline for injection) is the first listed.
NCT00764634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00764634 about?
NCT00764634 is a clinical study titled "Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B". This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
What is the current status of trial NCT00764634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 440 participants. The study started on 2008-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00764634?
The interventions under investigation include: Placebo (USP sterile saline for injection) (BIOLOGICAL), rBV A/B-40 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00764634?
This trial is sponsored by DynPort Vaccine Company LLC, A GDIT Company, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.